FDA panel rejects 1 of 7 peptides for compounding list

The Pharmacy Compounding Advisory Committee backed six peptides for the 503A Bulks list despite FDA staff objections over limited safety and efficacy evidence.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.